Neuralstem Investigator Presents New ALS NSI-566 Data at International Symposium on ALS/MND | #ALS AWARENESS #LouGehrigsDisease #PARKINSONS | Scoop.it
From www.heraldonline.com - December 11, 2012 7:29 AM

Neuralstem, Inc. (NYSE MKT: CUR) announced that Jonathon Glass, MD, Director of the Emory ALS Center, presented new data from the Phase I trial of Neuralstem's human spinal cord stem cells, NSI-566, in amyotrophic lateral sclerosis...